# A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

> **NCT05114603** · PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Melanoma

## Interventions

- **DRUG:** HLX208

## Key facts

- **NCT ID:** NCT05114603
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-21
- **Primary completion:** 2023-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05114603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05114603, "A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05114603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*